Sensitive detection of MPLW515L/K mutations by amplification refractory mutation system (ARMS)-PCR

Clinica Chimica Acta

Volumn 411, Issue 1-2, 2010, Pages 122-123

  Zhuge, Jian ^a   Zhang, Wei ^a   Xu, Mingjiang ^a   Hoffman, Ronald ^a   Zhang, Wenyong ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR GEL ELECTROPHORESIS; AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION; ASSAY; BLOOD CELL; CASE REPORT; GENE AMPLIFICATION; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION;

BASE SEQUENCE; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, THROMBOPOIETIN;

EID: 70449530413     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.10.012     Document Type: Letter

References (13)

1. Kilpivaara O., and Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22 (2008) 1813-1817
2. Beer P.A., Campbell P.J., Scott L.M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112 (2008) 141-149
3. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
4. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
5. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Characteristics and clinical correlates of MPL 515 W > L/K mutation in essential thrombocythemia. Blood 112 (2008) 844-847
6. Chaligne R., Tonetti C., Besancenot R., et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 22 (2008) 1557-1566
7. Thiele J., Kvasnicka H.M., Tefferi A., Barosi G., Orazi A., and Wardiman J.W. Primary myelofibrosis. In: Swerdlow S.H., Campo E., and Harris N.L. (Eds). WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. (2008), International Agency for Research on Cancer, Lyon
8. Guglielmelli P., Pancrazzi A., Bergamaschi G., et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137 (2007) 244-247
9. Pancrazzi A., Guglielmelli P., Ponziani V., et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagnostics 10 (2008) 435-441
10. Chen Q., Lu P., Jones A.V., Cross N.C., Silver R.T., and Wang Y.L. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagnostics 9 (2007) 272-276
11. Percy M.J., and McMullin M.F. The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol 23 (2005) 91-93
12. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
13. Packham D., Ward R.L., Ap Lin V., Hawkins N.J., and Hitchins M.P. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol 18 (2009) 62-71